Guggenheim reiterates Buy rating on Oruka Therapeutics, $200 price target
Guggenheim reaffirmed a Buy rating on Oruka Therapeutics, setting a $200 price target, implying a 121.4% upside from the last close. The firm cited positive Phase IIb study results for ORKA-001, with a 61% PASI-100 response rate, and projected peak sales of $7 billion, indicating strong market potential.
How this was made
The 30-second read
Why it matters
The trial's 61% PASI‑100 response aligns with expectations, supporting a $200 price target and a 121% upside estimate.
Market read
New clinical data could trigger a re‑rating of Oruka and affect related biotech stocks.
What to watch
Manufacturing scale‑up risks and competition from other IL‑23 inhibitors may temper price gains.
Background
Oruka Therapeutics (NASDAQ: ORKA) focuses on IL‑23 monoclonal antibodies for psoriasis. The EVERLAST‑B Phase IIb trial data were released in this analyst note.
Ticker impact
Guggenheim reiterated a Buy rating on Oruka Therapeutics and disclosed Phase IIb EVERLAST‑B trial data showing 61% PASI‑100 response, a new primary clinical result.
likely upward pressure as investors price in the strong efficacy data and high sales forecast.
First public disclosure of Phase IIb results for ORKA‑001; analysts project $7 bn peak sales, prompting a 121% upside target.
Market effects
Strengthens the IL‑23 monoclonal antibody segment and may boost peer biotech valuations.
U.S. biotech sector gains confidence from a promising psoriasis candidate.
Potentially influences global psoriasis treatment market dynamics.
Counterpoint
If later-stage data falters or regulatory hurdles arise, the upside could be overstated.
Key entities
- analystGuggenheim
Equity research firm that issued the Buy rating and price target.
- companyOruka Therapeutics
Biotech company developing ORKA‑001 for psoriasis.
